AUTHORS
Yi-Bin Chen, MD,MS, Saar Gill, MD, PhD2, Tania Jain, MBBS3, Alla Keyzner, MD4, Mathew G. Angelos, MD, PhD5, Anson Snow, MD6, Uday Popat, MD, MBA7, Melhem Solh, MD8, Michele Donato, MD9, Luis Pineiro, MD10, Sameem Abedin, MD11, Lohith Gowda, MD12, Joseph Uberti, MD, PhD13, Timothy White14, Yun Wang15, Erica Buonomo16, Sarah C. Potter17, Tatiana Oreshina18, Chrystal Louis, MD, MPH19, Shrikanta Chattopadhyay, MBBS20, Michelle Matzko, MD, PhD21, Ran Reshef, MD, MSc22, Monzr M. M Al Malki, MD23
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Abramson Cancer Center and Hospital of the University of Pennsylvania, Philadelphia, Massachusetts, United States
3 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
4 Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States
5 University of Colorado, Aurora, Colorado, United States
6 The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 Northside Hospital Cancer Institute, Atlanta, Georgia, United States
9 Hackensack University Medical Center, Hackensack, New Jersey, United States
10 Baylor University Medical Center, Dallas, Texas, United States
11 Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 Yale School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
13 Karmanos Cancer Institute, Detroit, Michigan, United States
14 TScan Therapeutics, Waltham, Massachusetts, United States
15 TScan Therapeutics, Waltham, Massachusetts, United States
16 TScan Therapeutics, Waltham, Massachusetts, United States
17 TScan Therapeutics, Waltham, Massachusetts, United States
18 TScan Therapeutics, Waltham, Massachusetts, United States
19 TScan Therapeutics, Waltham, Massachusetts, United States
20 TScan Therapeutics, Waltham, Massachusetts, United States
21 TScan Therapeutics, Waltham, Massachusetts, United States
22 Columbia University Irving Medical Center, New York, New York, United States
23 City of Hope, Duarte, California, United States
ABSTRACT
Relapse remains the leading cause of death after reduced-intensity conditioning (RIC)-based allogeneic hematopoietic cell transplantation (HCT) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with 1-year relapse rates of 55-64% in patients with minimal residual disease (MRD) or ELN adverse risk prior to HCT. These poor outcomes underscore a critical need for post-transplant strategies that promote anti-leukemia activity and mitigate relapse.
TSC-101 is an allogeneic, donor-derived, T-cell receptor-engineered T-cell (TCR-T) immunotherapy designed to eliminate residual recipient cancer cells post-RIC HCT by targeting the HA-2 antigen presented only by HLA-A*02:01-positive hematopoietic cells. By pairing HLA-A*02:01-positive subjects with HLA-A*02-negative transplant donors, TSC-101 can selectively eliminate residual recipient cells while sparing healthy donor-derived cells.
The ALLOHA™ Trial (NCT05473910) is a multi-center, biologically controlled, Phase 1 trial evaluating TSC-101 in adults with AML, acute lymphoblastic leukemia (ALL) or MDS undergoing RIC HCT with a haploidentical or mismatched unrelated donor (MMUD). In Cohort C, subjects received TSC-101 manufactured using the commercial-ready process. Subjects received their first TSC-101 infusion after engraftment (~Day 21 post RIC HCT) and a second infusion approximately 40 days later without lymphodepletion chemotherapy. Endpoints include dose-limiting toxicities (DLTs), safety, and efficacy; exploratory endpoints include chimerism, MRD, and TCR-T cell kinetics.
As of 6 July 2026, 14 subjects (8 with AML, 5 with MDS, & 1 with ALL) were included in the safety analysis set for Cohort C. Thirteen subjects received dose level (DL) 4 [first infusion ~0.8×109 TCR-T cells and second infusion ~1.6×109 TCR-T cells] and 1 subject received DL 3 [first infusion ~5×106 TCR-T cells/kg and second infusion ~ 2×107 TCR-T cells/kg] per protocol with the initial use of a MMUD. The median follow-up (range) was 3.9 (3-8) months. Baseline prognostic features included mutated TP53 (mTP53) status in 4/14 (28.6%) and pre-RIC HCT MRD positivity by next generation sequencing in 12/14 (86%).
The safety profile of TSC-101 was consistent with previously reported adverse events (Al Malki et al., Blood 2025. Abstract 12098). Treatment-emergent serious adverse events were reported in 5/14 (36%) subjects. Treatment-emergent acute graft-versus-host disease (aGvHD) of any grade occurred in 5/14 (36%) subjects, including Grade II-IV aGvHD in 2/14 (14%) subjects. Treatment-emergent chronic GvHD (mild) occurred in 1/14 (7%) subject. Following TSC-101 administration, treatment-emergent cytokine release syndrome (Grade 1) was reported in 1 (7%) subject. There were no reported events of immune effector cell-associated neurotoxicity syndrome, tumor lysis syndrome, or graft failure.
Translational analysis with a high-sensitivity chimerism assay (AlloHeme™) showed that 12/14 (86%) subjects had mixed chimerism in whole blood, CD33+ cells, or CD3+ cells after RIC HCT and prior to first TSC-101 infusion. Complete donor chimerism (>99.8%) was achieved in 11/14 (79%) evaluable subjects approximately 3 weeks after the 1st TSC-101 infusion and in 9/10 (90%) evaluable subjects approximately 3 weeks after the 2nd infusion.
To date, 2/14 (14%) subjects have relapsed, including one subject found to have a non-synonymous JAK1 mutation and low percentage of recipient blood cells positive for HLA-A*02 cell surface expression, and one additional subject has died due to sepsis. Of those MRD-positive prior to RIC HCT, 9/12 (75%) subjects are alive and in remission.
In conclusion, the ALLOHA™ Cohort C safety profile remains consistent with no new safety signals identified. Preliminary analyses demonstrate early efficacy, including in high-risk subjects with MRD-positive disease or TP53 mutated prior to RIC HCT, using TSC-101 manufactured using the commercial-ready process. These data further support the evaluation of TSC-101 in the pivotal
ALLOHA-2™ (NCT07702578) Phase 3 trial to improve relapse-free survival in subjects with AML and MDS after RIC HCT. Updated data will be presented at the meeting.
DISCLOSURES
Yi-Bin Chen, MD,MS: Novo Nordisk - Consultancy (Includes expert testimony); Daiichi - Consultancy (Includes expert testimony); Maat Pharma - Consultancy (Includes expert testimony); Nestle - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); TScan - Consultancy (Includes expert testimony); Medexus - Consultancy (Includes expert testimony)